OCUP - Ocuphire completes enrollment in mid-stage presbyopia study

Ocuphire Pharma (OCUP) has completed enrollment in the VEGA-1 Phase 2 clinical trial evaluating the safety and efficacy of a combination kit of Nyxol and low-dose pilocarpine in presbyopia, an eye disease associated with aging.A total of 150 subjects (planned target was 140 to 152) have been enrolled at 17 investigational sites in the US from mid-February to mid-May this year, the company said.The trial is a randomized, double-masked, placebo-controlled study with 4 treatment arms, with the primary endpoint of improvement in photopic binocular near vision.Top-line results from the study are expected by the end of Q2 2021.An estimated 120M Americans live with presbyopia, a large prevalence that is expected to exceed 150M by 2034.

For further details see:

Ocuphire completes enrollment in mid-stage presbyopia study